The Glioblastoma Drug Discovery Group announces that osimertinib significantly prolongs the survival of immunocompromised mice bearing intracranial EGFRvIII-positive glioblastoma! These data warrant the commencement of studies designed to test osimertinib’s safety and efficacy in GBM patients.
Menu
magnificent submit, very informative. I ponder why the other experts of this sector don’t understand this.
You must proceed your writing. I am confident, you have a huge
readers’ base already!